Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus

被引：19
|
作者：
Jamaluddin, Jazlina Liza [1 ]
Huri, Hasniza Zaman [1 ,2 ]
Vethakkan, Shireene Ratna [3 ]
机构：
[1] Univ Malaya, Dept Pharm, Fac Med, Kuala Lumpur 50603, Malaysia
[2] Univ Malaya, Med Ctr, Clin Invest Ctr, 13th Floor Main Tower, Kuala Lumpur 59100, Malaysia
[3] Univ Malaya, Fac Med, Dept Med, Endocrinol Unit, Kuala Lumpur 50603, Malaysia
来源：
PHARMACOGENOMICS | 2016年 / 17卷 / 08期
关键词：
DPP4; dipeptidyl peptidase-4 inhibitors; HbA1c; KCNJ11; Type 2 diabetes mellitus; WFS1; HOMEOSTASIS MODEL ASSESSMENT; GLUCAGON-LIKE PEPTIDE-1; INSULIN-RESISTANCE; BLOOD-PRESSURE; DPP-4; INHIBITORS; E23K VARIANT; THERAPEUTIC RESPONSE; IV INHIBITION; WFS1; GENE; ASSOCIATION;
D O I：
10.2217/pgs-2016-0010
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Aim: To determine the clinical and genetic predictors of the dipeptidyl peptidase-4 (DPP-4) inhibitor treatment response in Type 2 diabetes mellitus (T2DM) patients. Patients & methods: DPP4, WFS1 and KCNJ11 gene polymorphisms were genotyped in a cohort study of 662 T2DM patients treated with DPP-4 inhibitors sitagliptin, vildagliptin or linagliptin. Genotyping was performed by Applied Biosystems TaqMan SNP genotyping assay. Results: Patients with triglyceride levels less than 1.7 mmol/l (odds ratio [OR]: 2.2.; 95% CI: 1.031-4.723), diastolic blood pressure (DBP) less than 90 mmHg (OR: 1.7; 95% CI: 1.009-2.892) and KCNJ11 rs2285676 (genotype CC) (OR: 2.0; 95% CI: 1.025-3.767) were more likely to response to DPP-4 inhibitor treatment compared with other patients, as measured by HbA1c levels. Conclusion: Triglycerides, DBP and KCNJ11 rs2285676 are predictors of the DPP-4 inhibitor treatment response in T2DM patients.
引用
收藏
页码：867 / 881
页数：15
相关论文
共 50 条
12345